Conotoxins - blueprints for GPCR drug discovery?
Markus Muttenthaler(The University of Queensland), P.F. Alewood, David J. Adams(University of Wollongong), Richard J. Lewis(AstraZeneca (Netherlands)), Sébastien Dutertre(École Nationale Supérieure de Chimie de Montpellier), Simon T. Nevin(The University of Queensland), C. W. Gruber, David J. Craik(The University of Queensland), Norelle L. Daly(Australian Institute of Tropical Health and Medicine), Irina Vetter(Centre National de la Recherche Scientifique), А. А. Гришин, Åsa Andersson
Queensland's institutional digital repository (The University of Queensland)
January 1, 2011
Cited by 0
Related Papers
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
|Nature Medicine|2015|2.8k
Methods Used to Evaluate Pain Behaviors in Rodents
|Frontiers in Molecular Neuroscience|2017|1.3k
Therapeutic potential of venom peptides
|Nature Reviews Drug Discovery|2003|786
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
|Frontiers in Molecular Neuroscience|2017|654
Conus Venom Peptide Pharmacology
|Pharmacological Reviews|2012|422